Humanigen, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Kalobios Pharmaceuticals, Inc. (to 2017)
2
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 2 to 13, 2026 · next Dec 2
- 1 fee due Feb 18, 2027The maintenance fee for Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow (US 9,109,032) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Antibodies to EphA3 (US 9,290,571) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,183 | Antibodies to granulocyte-macrophage colony-stimulating factor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,017,674 | Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor In force · Low confidence | In force | Low confidence | |
| US 9,290,571 | Antibodies to EphA3 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,834,870 | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 In force · From the USPTO record | In force | From the USPTO record | |
| US 9,045,539 | Anti-EMR1 antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 9,109,032 | Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow In force · From the USPTO record | In force | From the USPTO record | |
| US 10,870,703 | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist In force · From the USPTO record | In force | From the USPTO record | |
| US 10,899,831 | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity In force · From the USPTO record | In force | From the USPTO record | |
| US 10,927,168 | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab In force · From the USPTO record | In force | From the USPTO record | |
| US 11,130,805 | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 1 patent in force now held by others · 3 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 10 no status recorded